It has to be noted that EPO biosimilar comparison studies indicate that the products marketed in Europe vary from those developed and marketed by companies in semi-regulated markets 2,3.
February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar. February brought policy updates and several biosimilar approvals, ...
The Global Oncology Biosimilars Market is expected to grow at 18.5% CAGR from 2025 to 2032. The latest Research report published by CMI with the title "An Increase in Demand and Opportunities for ...
Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.
Consistent with its mission of delivering affordability without compromising access, MedImpact’s approach to biosimilars is pharmacy- and manufacturer-neutral. “Stelara has long been a cornerstone ...
India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...
A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...
(Reuters) - Johnson & Johnson (NYSE:JNJ) sued Samsung (KS:005930) Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis ...
Alvotech (NASDAQ:ALVO) and Teva Pharmaceuticals (NYSE:TEVA) said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application for a biosimilar targeting Regeneron’s (REGN ...
Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.